The Effectiveness of Antiviral Treatments for Patients with HBeAg-Positive Chronic Hepatitis B: A Bayesian Network Analysis

Table 1

Main characteristics of studies included.

Study	Country	Year	Project	Initial Treatment	Include patients	End point	Randomized Treatment	Jada Scores
Chi H et al. [8]	Netherlands, China	2017	NCT01532843	≥12wk ETV or TDF	HBV DNA <2 000 IU/mL, ALT<5 times the upper limit of normal	ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion	NA, NA add-on PEG IFN	2
Sun J et al. [9]	China	2016	NCT01086085	24wk PEG IFN	Non early responders	ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion	PEG IFN, PEG IFN add- on NA	2
Brouwer WP et al. [6]	Europe, Asia	2015	NCT00877760	24wk ETV	ALT >1.3 times the upper limit of normal	ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion	NA, NA add-on PEG IFN	2
Xie Q et al. [10]	China	2014	NCT00614471	NA	HBV DNA ≥100 000 copies/mL, ALT >2 but ≤10 times the upper limit of normal	ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion	PEG IFN, NA and PEG IFN add-on NA	2
Liu YH et al. [11]	China	2014	-	NA	HBV DNA ≥100 000 copies/mL, ALT >2 but ≤10 times the upper limit of normal	ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion	PEG IFN, PEG IFN combined NA	1
Ning Q et al. [7]	China	2014	OSST	9-36 months ETV	HBV DNA <1000copies/mL, HBeAg<100PEIU/L	ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion	NA, NA switch PEG IFN	2
Lau GK et al. [12]	16 countries	2005	-	NA	HBsAg negative, HBV DNA ≥500 000 copies/mL, ALT >1 but ≤10 times the upper limit of normal	ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion	NA, PEG IFN combined PLA, and PEG IFN combined NA	3
Chan HL et al. [13]	Hong Kong	2005	-	-	HBV DNA ≥500 000 copies/mL, ALT >1.3 but ≤5 times the upper limit of normal	ALT normalization, HBV DNA undectable, and HBeAg seroconversion	PEG IFN add-on NA, NA	2
Janssen HL et al. [14]	15 countries	2005	-	-	ALT >2 times the upper limit of normal	ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion	PEG IFN combined NA, PEG IFN combined PLA	3

Note: NA, nucleoside/nucleotide analogs; PEG IFN, PEG IFNylated interferon; PLA, placebo; ETV, entecavir; TDF, tenofovir; wk, week